Theravance Biopharma (TBPH) Current Leases (2019 - 2026)

Theravance Biopharma (TBPH) has 8 years of Current Leases data on file, last reported at $10.8 million in Q1 2026.

• Current Leases for Q1 2026 came in at $10.8 million, down 0.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.8 million (down 0.51% YoY), and the FY2025 annual result was $10.9 million, up 2.18% from the prior year.
• Current Leases slipped to $10.8 million in Q1 2026 per TBPH's latest filing, from $10.9 million in the prior quarter.
• Over five years, Current Leases peaked at $10.9 million in Q4 2025 and troughed at $692000.0 in Q3 2022.
• A 5-year average of $7.2 million and a median of $7.4 million in 2023 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2024: Current Leases surged 1303.61% in 2023, then slumped 56.8% in 2024.
• A 5-year view of Current Leases shows it stood at $6.8 million in 2022, then slumped by 41.91% to $3.9 million in 2023, then jumped by 173.06% to $10.7 million in 2024, then grew by 2.18% to $10.9 million in 2025, then decreased by 1.76% to $10.8 million in 2026.
• Business Quant data shows TBPH's Current Leases at $10.8 million in Q1 2026, $10.9 million in Q4 2025, and $10.9 million in Q3 2025.